Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Viruses Cause Debilitating Human Diseases
- Genomics and Antiviral Development
- Current Anti-Infectives Markets
- Major Companies
- Top-Selling Brands
- Impact of Combination Products
- Gilead Sciences' HIV Franchise
- GlaxoSmithKline' s HIV Franchise
- Antiviral Drug Classes
- Herpes Polymerase Inhibitors
- Nucleoside Analogue Reverse Transcriptase Inhibitors
- Nucleoside Analogues
- Neuraminidase Inhibitors
- Other HIV Antiviral Classes
- Antivirals in Clinical Development
- Small Molecules
- HCV Antivirals
- HIV Antivirals
- New Classes of Antivirals in Clinical Development
- Biologics
- Industry-Shaping Events
- Recent Deals and Business Strategies
- Alnylam and Cubist
- Bristol-Myers Squibb and ZymoGenetics
- GlaxoSmithKline and Pfi zer
- GlaxoSmithKline and Santaris Pharma
- Merck & Co. and Ranbaxy Laboratories
- Pfi zer and Tacere Therapeutics
- Roche and Metabasis Therapeutics
- Market Drivers
- New Mechanisms of Action
- Improved Dosing and Patient Compliance
- Dominance of Small Molecules Over Biologics
- Emerging Markets
- Emerging Viruses
- Outlook
Tables
- 1. The Link Between Human Viruses and Disease 7
- 2. Gilead Sciences' and GlaxoSmithKline' s Major Antiviral HIV Franchises,
2008 11
- 3. New Classes of Small-Molecule Antivirals in Clinical Development 17
- 4. Select Monoclonal Antibodies in Clinical Development as Antivirals,
2009 18
- 5. Select RNA-Based Therapeutics in Development as Antivirals 19
Figures
- 1. Growth in the Global Anti-Infectives Markets, 2007-2014 8
- 2. Major Companies Marketing Antivirals, 2008 9
- 3. Best-Selling Antiviral Brands, 2008 10
- 4. Small-Molecule Antivirals by Phase of Clinical Development, 2008 14
- 5. Market Share of HIV Antiviral Drug Classes, 2007 15
|
Related Report
|
View Cart
